Donepezil

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Postoperative Complications

Conditions

Postoperative Complications, Delirium

Trial Timeline

Feb 1, 2005 → Apr 1, 2007

NCT ID

NCT00182845

About Donepezil

Donepezil is a approved stage product being developed by Pfizer for Postoperative Complications. The current trial status is completed. This product is registered under clinical trial identifier NCT00182845. Target conditions include Postoperative Complications, Delirium.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00174382	Phase 3	Terminated	Jun 1, 2005	Apr 1, 2008	Dementia, Vascular
NCT00182845	Approved	Completed	Feb 1, 2005	Apr 1, 2007	Postoperative Complications
NCT00196690	Approved	Completed	Feb 1, 2003	Mar 1, 2005	Stroke

Competing Products

20 competing products in Postoperative Complications

See all competitors

Product	Company	Stage	Hype Score
Naldemedine + Placebo	Shionogi	Phase 2	52
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IV	Eisai	Approved	85
Lemborexant 5 mg + Control (placebo) group	Eisai	Phase 2	52
Ondansetron + Palonosetron	Eisai	Phase 2	52
AQUAVAN (fospropofol disodium; GPI 15715 )	Eisai	Phase 2	52
ONO-1101	Ono Pharmaceutical	Phase 2	52
ONO-1101	Ono Pharmaceutical	Phase 2/3	65
Levofloxacin Ophthalmic + Cefuroxime	Santen Pharmaceutical	Phase 1/2	41
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic Solution	Santen Pharmaceutical	Phase 1/2	41
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparation	Jiangsu Hengrui Medicine	Phase 1	33
SHR0410 Injection + SHR0410 Injection + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
SHR8554 Injection	Jiangsu Hengrui Medicine	Phase 1	33
Esomeprazole	AstraZeneca	Approved	85
deep neuromuscular block	Merck	Pre-clinical	23
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + Placebo	Merck	Phase 2	52
MK0966, rofecoxib + Comparator: valdecoxib	Merck	Phase 3	77
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, Placebo	Merck	Approved	85
MK0719	Merck	Phase 2	52
Sugammadex + Neostigmine	Merck	Approved	85
MK0869, aprepitant + Comparator: ondansetron IV	Merck	Phase 3	77

Other Products from Pfizer